natgillin/translations-raw huggingface dataset:
If you forget to take Xyrem If you forget to take the first dose, take it as soon as you remember and then continue as before.
Če ste pozabili vzeti zdravilo Xyrem Če ste pozabili vzeti prvi odmerek, ga vzemite takoj, ko se spomnite, in nato nadaljujte z jemanjem zdravila kot prej.
If you stop taking Xyrem You should continue to take Xyrem for as long as instructed by your Doctor.
Če ste prenehali jemati zdravilo XyremZdravilo Xyrem morate jemati tako dolgo, kot vam je naročil vaš zdravnik.
You may find that your cataplexy attacks return if your medicine is stopped and you may experience insomnia, headache, anxiety, dizziness, sleeping problems, sleepiness, hallucination and abnormal thinking.
Če boste prenehali jemati zdravilo, se lahko zopet pojavijo kataplektični napadi ter tudi nespečnost, glavobol, občutek tesnobe, omotičnost, težave s spanjem, zaspanost, halucinacije in motnje mišljenja.
Like all medicines, Xyrem can have side effects.
Kot vsa zdravila ima lahko tudi zdravilo Xyrem neželene učinke Ti so običajno blagi do zmerni.
Sodium oxybate has a well known abuse potential.
Pri zdravilu Xyrem je dobro znana možnost zlorabe.
No cases of abuse are known among individuals treated for narcolepsy.
Pri posameznikih, ki so se z zdravilom zdravili zaradi narkolepsije, niso znani primeri zlorabe.
However cases of dependency have occurred after the illicit use of sodium oxybate.
Pri prepovedani uporabi natrijevega oksibata so se pojavili primeri odvisnosti.
Nausea, dizziness, headache
Zelo pogosti neželeni učinki so: slabost, omotičnost, glavobol
Sleeping problems including insomnia, blurred vision, vomiting, stomach pains, diarrhoea, anorexia, weakness, abnormal dreams, tiredness, feeling drunk, sleep paralysis, sleepiness, trembling, confusion/ disorientation, nightmares, sleep walking, bed wetting, sweating, depression, muscle cramps, swelling, fall, joint pain, cataplexy, balance disorder, disturbance in attention, disturbed sensitivity particularly to touch, abnormal touch sensation, sedation, anxiety, difficulty in falling asleep in the middle of the night, nervousness, urinary incontinence, shortness of breath, snoring
Pogosti neželeni učinki so: težave pri spanju vključno z nespečnostjo, zamegljen vid, bruhanje, bolečine v želodcu, driska, anoreksija, šibkost, neobičajne sanje, utrujenost, občutek pijanosti, paraliza v spanju, zaspanost, drgetanje, zmedenost/ motnje orientacije, nočne more, hoja v spanju, močenje postelje, potenje, depresija,, mišični krči, otekline, padec, bolečine v sklepih, katapleksija, motnje ravnotežja, motnje pozornosti, motena občutljivost, še posebej na dotik, nenormalen občutek na dotik, sedacija, tesnoba, težave zaspati sredi noči, živčnost, nezmožnost zadrževanja urina, oteženo dihanje, smrčanje
Psychosis (a mental disorder that may involve hallucinations, incoherent speech, or disorganized and agitated behavior), paranoia, abnormal thinking, hallucination, agitation, suicide attempt, difficulty in falling asleep, restless legs, weight loss, forgetfulness, myoclonus (involuntary contractions of muscles), involuntary passage of feces, rash, increased blood pressure
Občasni neželeni učinki so: psihoza (duševna motnja, ki lahko vključuje halucinacije, nepovezan govor ali neorganizirano in razburjeno vedenje), paranoja, motnje mišljenja, halucinacije, agitacija (vznemirjenost), poskus samomora, s težavo zaspati, nemirne noge, izguba telesne mase, pozabljivost, mioklonus (nehoteno krčenje mišic), nehoteno uhajanje blata, izpuščaj, povišan krvni tlak
Convulsion, decreased breathing depth or rate, hives, hypersensitivity, suicidal thoughts
Neželeni učinki z neznano pogostnostjo so: konvulzija (napad krčev), zmanjšana globina ali hitrost dihanja, koprivnica, preobčutljivost, misli o samomoru
If any of these affect you severely, tell your doctor.
Če kateri od navedenih neželenih učinkov močno vpliva na vas, povejte svojemu zdravniku.
If you are concerned about any side effect, or if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist.
Če ste zaskrbljeni zaradi katerega od neželenih učinkov ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
HOW TO STORE XYREM
SHRANJEVANJE ZDRAVILA XYREM
Do not use Xyrem after the expiry date stated on the bottle.
Zdravila Xyrem ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki.
Do not store Xyrem solutions diluted with water for more than 24 hours.
Z vodo razredčene raztopine zdravila Xyrem ne smete shranjevati več kot 24 ur.
What Xyrem contains
Kaj vsebuje zdravilo Xyrem
- The active substance is sodium oxybate.
- Zdravilna učinkovina je natrijev oksibat.
- The other ingredients are purified water, malic acid and sodium hydroxyde.
- Pomožne snovi so prečiščena voda, jabolčna kislina in natrijev hidroksid
Xyrem is supplied as an oral solution in a 180 ml tamper-evident amber plastic bottle.
Zdravilo Xyrem je peroralna raztopina, ki je na voljo v 180- mililitrski rjavi plastenki, zaščiteni pred nedovoljenim odpiranjem.
Each pack contains one bottle, a press-in-bottle-adaptor (PIBA), a plastic measuring syringe and two dosing cups with child-resistant caps.
V vsakem pakiranju je ena plastenka, adapter, ki se pritisne v plastenko (PIBA - press- in- bottle- adaptor), plastična merilna injekcijska brizga in dve odmerni merici z za otroke varnima zaporkama.
What Xyrem looks like and contents of the pack Xyrem is a clear to slightly opalescent solution.
Izgled zdravila Xyrem in vsebina pakiranja Zdravilo Xyrem je bistra do rahlo opalescentna raztopina.
The amber plastic bottle contains 180 ml of oral solution.
Rjava plastenka vsebuje 180 ml peroralne raztopine.
Marketing Authorisation Holder:
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet:
Manufacturer:
UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire, SL1 3WE, Velika Britanija Izdelovalec:
Recipharm Limited, Vale of Bardsley, Ashton-under-Lyne, Lancashire, OL7 9RR, United Kingdom.
Recipharm Limited, Vale of Bardsley, Ashton- under- Lyne, Lancashire, OL7 9RR, Velika Britanija.
UCB Pharma Ltd, Unit 11 - 14 Foster Avenue, Woodside Park, Dunstable, Bedfordshire LU5 5TA, United Kingdom UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire SL1 3WE, United Kingdom
UCB Pharma Ltd, Unit 11 - 14 Foster Avenue, Woodside Park, Dunstable, Bedfordshire LU5 5TA, Velika Britanija UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire SL1 3WE, Velika Britanija
You should have received a Xyrem Information Pack from your physician, which includes a booklet all about Xyrem and a video showing you how to take the product.
Od zdravnika morate prejeti tudi Zavitek z informacijami o zdravilu Xyrem, ki vsebuje brošuro o zdravilu Xyrem in video, ki vam bo pokazal, kako jemati zdravilo.
If you have not received this, please contact the local representative of the Marketing Authorisation Holder, below.
Če tega niste prejeli, se obrnite na predstavništvo imetnika dovoljenja za promet, ki je naveden spodaj.
Tel: + 353 / (0)1-46 37 395
Tel: + 353 / (0) 1 46 37 395
< ------------------------------------------------------------------------------------------------------------------------------
< ----------------------------------------------------------------------------------------------------------------
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu
It works by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Deluje tako, da živčnim prenašalcem 5- hidroksitriptamina (imenovanim tudi serotonin) in noradrenalinu preprečuje ponovno vezavo na živčne celice v možganih in hrbtenjači.
How duloxetine works in SUI is not clear but it is thought that, by increasing the levels of 5-hydroxytryptamine and noradrenaline at the level of the nerves that control the muscle of the urethra (the tube that leads from the bladder to outside), duloxetine causes a stronger closure of the urethra during urine storage.
Način delovanja zdravila pri stresni urinski inkontinenci ni jasen, vendar se domneva, da duloksetin s povečevanjem ravni 5- hidroksitriptamina in noradrenalina na raven v živcih, ki nadzorujejo mišice sečnice (izvodilo iz sečnega mehurja navzven), okrepi stisk mišic zapiralk sečnice med shranjevanjem urina.
Reproduction is authorised provided the source is acknowledged. dummy treatment).
Kako je bilo zdravilo Yentreve raziskano?
The main measures of effectiveness were incontinence episode frequency (IEF, the number of episodes of incontinence per week) recorded in patient diaries and the patients’ scores on an incontinence-specific quality-of-life questionnaire (I-QOL).
Glavni merili učinkovitosti sta bili pogostnost inkontinenčnih epizod (IEF, tj. število inkontinenčnih epizod na teden), razvidno iz dnevnikov zdravljenja ter bolnikovega števila točk po vprašalniku o kakovosti življenja, specifičnem za inkontinenco (I- QOL).
The IEF decreased by 52% in the Yentreve group, compared with a decrease of 33% in the placebo-treated group.
Pogostnost inkontinenčnih epizod se je v skupini bolnic, ki so prejemale zdravilo Yentreve, zmanjšala za 52%, v primerjavi s skupino bolnic, ki so prejemale placebo, pa se je zmanjšala za 33%.
The I-QOL questionnaire scores were also improved in the Yentreve group compared with the placebo group.
V skupini bolnic, ki so prejemale zdravilo Yentreve, se je izboljšal tudi rezultat po vprašalniku I- QOL v primerjavi s skupino bolnic, ki so prejemale placebo.
Yentreve should not be used with monoamine oxidase inhibitors (a group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic).
Zdravilo Yentreve se ne sme uporabljati z zaviralci monoamin- oksidaze (skupino zdravil proti depresiji), fluvoksaminom (drugim zdravilom proti depresiji) ali ciprofloksacinom in enoksacinom (vrsti antibiotika).
The Committee for Medicinal Products for Human Use (CHMP) decided that Yentreve’ s benefits are greater than its risks for the treatment of moderate to severe SUI.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Yentreve pri zdravljenju zmerne do hude stresne urinske inkontinence večje od z njim povezanih tveganj.
The European Commission granted a marketing authorisation valid throughout the European Union for Yentreve to Eli Lilly Nederland B. V. on 11 August 2004.
Evropska komisija je dovoljenje za promet z zdravilom Yentreve, veljavno po vsej Evropski uniji, odobrila družbi Eli Lilly Nederland B. V. dne 11. avgusta 2004.
Hard gastro-resistant capsules Hard gastro-resistant capsules Hard gastro-resistant capsules Hard gastro-resistant capsules Hard gastro-resistant capsules Hard gastro-resistant capsules Hard gastro-resistant capsules Hard gastro-resistant capsules
trde gastrorezistentne kapsule trde gastrorezistentne kapsule trde gastrorezistentne kapsule trde gastrorezistentne kapsule trde gastrorezistentne kapsule trde gastrorezistentne kapsule trde gastrorezistentne kapsule trde gastrorezistentne kapsule
Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo za peroralno uporabo
blister (PVC/ PE/ PCTFE/ alu) blister (PVC/ PE/ PCTFE/ alu) blister (PVC/ PE/ PCTFE/ alu) blister (PVC/ PE/ PCTFE/ alu) blister (PVC/ PE/ PCTFE/ alu) blister (PVC/ PE/ PCTFE/ alu) blister (PVC/ PE/ PCTFE/ alu) blister (PVC/ PE/ PCTFE/ alu)
pretisni omot (PVC/ PE/ PCTFE/ alu) pretisni omot (PVC/ PE/ PCTFE/ alu) pretisni omot (PVC/ PE/ PCTFE/ alu) pretisni omot (PVC/ PE/ PCTFE/ alu) pretisni omot (PVC/ PE/ PCTFE/ alu) pretisni omot (PVC/ PE/ PCTFE/ alu) pretisni omot (PVC/ PE/ PCTFE/ alu) pretisni omot (PVC/ PE/ PCTFE/ alu)
YENTREVE 40 mg hard gastro-resistant capsules.
YENTREVE 40 mg trde gastrorezistentne kapsule
The capsule has an Opaque orange body, imprinted with ’ 40mg’ and an opaque blue cap, imprinted with ‘ 9545’.
Kapsula ima neprozorno oranžno telo z vtisnjenim napisom ‘ 40 mg ’ ter neprozoren moder pokrovček z vtisnjeno oznako ‘ 9545 ’.
YENTREVE is indicated for women for the treatment of moderate to severe Stress Urinary Incontinence (SUI), (see section 5.1).
4. 1 Terapevtske indikacije
After 2-4 weeks of treatment, patients should be re-assessed in order to evaluate the benefit and tolerability of the therapy.
Po 2 - 4 tednih zdravljenja je treba bolnice ponovno pregledati, da ovrednotimo učinkovitost in prenosljivost zdravljenja.
Combining YENTREVE with a pelvic floor muscle training (PFMT) program may be more effective than either treatment alone.
Kombiniranje jemanja zdravila YENTREVE s programom treninga mišic medeničnega dna (pelvic floor muscle training, PFMT) je lahko bolj učinkovito, kot če metodi zdravljenja uporabljamo posamezno.
YENTREVE should not be used in women with liver disease resulting in hepatic impairment (see section 4.3).
Okvarjeno delovanje jeter Zdravila YENTREVE ne smemo uporabljati pri ženskah z obolenjem jeter, katerega posledica je okvarjeno delovanje jeter (glejte poglavje 4. 3).
No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/ min).
Okvarjeno delovanje ledvic Pri bolnicah z blago do zmerno okvarjenim delovanjem ledvic (očistek kreatinina 30 do 80 ml/ min) odmerka ni treba prilagajati.
Caution should be exercised when treating the elderly.
Starejši Pri zdravljenju starejših je potrebna posebna previdnost.
The safety and efficacy of duloxetine in patients in these age groups have not been studied.
2 Otroci in mladostniki Varnosti in učinkovitosti duloksetina pri bolnikih v teh starostnih skupinah niso preučevali.
Therefore, administration of YENTREVE to children and adolescents is not recommended.
Zato dajanja zdravila YENTREVE otrokom in mladostnikom ne priporočamo.
When stopping treatment with YENTREVE the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8).
Ob prenehanju zdravljenja z zdravilom YENTREVE je treba odmerek zdravila v obdobju najmanj enega do dveh tednov postopoma zmanjševati, da zmanjšamo tveganje za pojav odtegnitvenih reakcij (glejte poglavji 4. 4 in 4. 8).
YENTREVE should not be used in combination with nonselective, irreversible Monoamine Oxidase Inhibitors - MAOIs (see section 4.5).
Zdravila YENTREVE ne smemo uporabljati v kombinaciji z neselektivnimi ireverzibilnimi zaviralci monoaminooksidaze - MAOI (glejte poglavje 4. 5).
YENTREVE should not be used in combination with CYP1A2 inhibitors, like fluvoxamine, ciprofloxacin or enoxacine since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).
Zdravila YENTREVE ne smemo uporabljati v kombinaciji z zaviralci CYP1A2, kot so fluvoksamin, ciprofloksacin ali enoksacin, ker kombinacija povzroči povišane plazemske koncentracije duloksetina (glejte poglavje 4. 5).
The initiation of treatment with YENTREVE is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and 4.8).
Uvedba zdravljenja z zdravilom YENTREVE je kontraindicirana pri bolnicah z nenadzorovano hipertenzijo, ki lahko izpostavi bolnice možnemu tveganju za hipertenzivno krizo (glejte poglavje 4. 4 in 4. 8).
Mania and Seizures YENTREVE should be used with caution in patients with a history of mania or a diagnosis of bipolar disorder, and/ or seizures.
Manija in epileptični napadi Zdravilo YENTREVE moramo pri bolnicah z manijo v anamnezi ali diagnozo bipolarne motnje in/ ali epileptičnimi napadi uporabljati previdno.
Use with antidepressants The use of YENTREVE in combination with antidepressants (especially with SSRI, SNRI and reversible MAOIs) is not recommended (see below “ Depression, suicidal ideation and behaviour” and Section 4.5).
Sočasna uporaba z antidepresivi Uporabe zdravila YENTREVE v kombinaciji z antidepresivi (zlasti v kombinaciji s SSRI, SNRI in reverzibilnimi MAOI) ne priporočamo (glejte spodaj “ Depresija, samomorilne misli in vedenje ” in poglavje 4. 5).
St John’ s wort Undesirable effects may be more common during concomitant use of YENTREVE and herbal preparations containing St John’ s wort (Hypericum perforatum).
Šentjanževka Ob sočasni uporabi zdravila YENTREVE in pripravkov rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perforatum), so lahko neželeni učinki pogostejši.
Mydriasis Mydriasis has been reported in association with duloxetine, therefore, caution should be used when prescribing duloxetine in patients with increased intraocular pressure, or those at risk of acute narrow- angle glaucoma.
Midriaza V povezavi z duloksetinom so poročali o midriazi, zato je pri predpisovanju bolnicam s povišanim intraokularnim tlakom ali s tveganjem za akutni glavkom z zaprtim zakotjem potrebna previdnost.
Duloxetine should be used with caution in patients whose conditions could be compromised by an increased heart rate or by an increase in blood pressure.
Previdnost je
Caution should also be exercised when duloxetine is used 3 with medicinal products that may impair its metabolism (see section 4.5).
3 potrebna tudi pri uporabi duloksetina z zdravili, ki lahko poslabšajo presnovo (glejte poglavje 4 5).
Haemorrhage There have been reports of bleeding abnormalities, such as ecchymoses, purpura and gastrointestinal haemorrhage with selective serotonin reuptake inhibitors (SSRIs) and serotonin/ norepinephrine reuptake inhibitors (SNRIs).
Krvavitev Pri selektivnih zaviralcih prevzema serotonina (selective serotonin reuptake inhibitors, SSRI) in selektivnih zaviralcih prevzema noradrenalina (selectivenorepinephrine reuptake inhibitors, SNRI) so poročali o nenormalnih krvavitvah, kot so ekhimoze, purpure in krvavitve iz prebavil.
Caution is advised in patients taking anticoagulants and/ or medicinal products known to affect platelet function, and in patients with known bleeding tendencies.
Pri bolnicah, ki jemljejo sredstva proti strjevanju krvi in/ ali druga zdravila, za katera je znano, da vplivajo na delovanje trombocitov, ter pri bolnicah z znano nagnjenostjo h krvavitvam je potrebna previdnost.
In a clinical trial adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with YENTREVE and 24% of patients taking placebo.
V kliničnih preskušanjih so se neželeni učinki ob nenadni prekinitvi zdravljenja pojavili pri približno 45% bolnic, ki so jemale zdravilo YENTREVE in pri 23% bolnic, ki so dobivale placebo.
Hyponatremia Hyponatremia has been reported rarely, predominantly in the elderly, when administering YENTREVE.
Hiponatriemija Ob dajanju zdravila YENTREVE so redko poročali o hiponatriemiji, zlasti pri starejših.
Caution is required in patients at increased risk for hyponatremia; such as elderly, cirrhotic, or dehydrated patients or patients treated with diuretics.
Previdnost je potrebna pri bolnicah z večjim tveganjem za hiponatriemijo; denimo pri starejših, bolnicah s cirozo, dehidriranih bolnicah ali bolnicah, ki jemljejo diuretike.
Depression, suicidal ideation and behaviour Although YENTREVE is not indicated for the treatment of depression, its active ingredient (duloxetine) also exists as an antidepressant medication.
Depresija, samomorilne misli in vedenje Čeprav zdravilo YENTREVE ni indicirano za zdravljenje depresije, njegova zdravilna učinkovina (duloksetin) obstaja tudi kot antidepresiv.
A meta-analysis of placebo- controlled clinical trials of antidepressants medicinal products in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old Cases of suicidal thoughts and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.8).
Med zdravljenjem z duloksetinom ali kmalu po prenehanju zdravljenja so poročali o primerih samomorilnih misli in samomorilnega vedenja (glejte poglavje 4. 8).
If while on YENTREVE therapy, the patient develops agitation or depressive symptoms, specialised medical advice should be sought, as depression is a serious medical condition.
Če bolnica med zdravljenjem z zdravilom YENTREVE postane agitirana ali razvije simptome depresije,
If a decision to initiate antidepressant pharmacological therapy is taken, the gradual discontinuation of YENTREVE is recommended (see Section 4.2).
V primeru, da se zdravnik odloči za farmakološko zdravljenje z antidepresivi, svetujemo postopno ukinjanje zdravila YENTREVE (glejte poglavje 4. 2).
4 Use in children and adolescents under 18 years of age No clinical trials have been conducted with duloxetine in paediatric populations.
Uporaba pri otrocih in mladostnikih, mlajših od 18 let Pri pediatričnih skupinah niso opravili kliničnih preskušanj z duloksetinom.
Long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.
Poleg tega so pomanjkljivi tudi podatki o dolgoročni varnosti pri otrocih in mladostnikih glede rasti, dozorevanja in kognitivnega ter vedenjskega razvoja.
Sucrose YENTREVE hard gastro-resistant capsules contain sucrose.
Saharoza YENTREVE trde gastrorezistentne kapsule vsebujejo saharozo.
Monoamine oxidase inhibitors (MAOIs): due to the risk of serotonin syndrome, YENTREVE should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Zaviralci monoaminooksidaze (MAOI): zaradi nevarnosti za serotoninski sindrom zdravila YENTREVE ne smemo uporabljati v kombinaciji z neselektivnimi ireverzibilnimi zaviralci monoaminooksidaze (MAOI) ali v 14 dneh po prenehanju zdravljenja z MAOI.
Based on the half-life of duloxetine, at least 5 days should be allowed after stopping YENTREVE before starting an MAOI (see section 4.3).
Na podlagi razpolovnega časa duloksetina mora po prenehanju jemanja zdravila YENTREVE preteči vsaj 5 dni pred začetkom jemanja MAOI (glejte poglavje 4. 3).
Serotonin syndrome: in rare cases, serotonin syndrome has been reported in patients using SSRIs concomitantly with serotonergic medicinal products.
Serotoninski sindrom: pri bolnikih, ki so uporabljali SSRI sočasno s serotoninergičnimi zdravili, so v redkih primerih poročali o serotoninskem sindromu.
The use of YENTREVE in combination with serotonergic antidepressants like SSRIs, tricyclics like clomipramine or amitriptyline, venlafaxine, or triptans, tramadol and tryptophan is not recommended.
Uporabe zdravila YENTREVE v kombinaciji s serotoninergičnimi antidepresivi, kot so SSRI, tricikličnimi antidepresivi, kot sta klomipramin ali amitriptilin, venlafaksinom ali triptani, tramadolom in triptofanom, ne priporočamo.
CNS medicinal products: caution is advised when YENTREVE is taken in combination with other centrally acting medicinal product or substances, including alcohol and sedative medicinal product (benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Zdravila CŽS: če se zdravilo YENTREVE jemlje v kombinaciji z drugimi osrednje delujočimi zdravili ali snovmi, vključno z alkoholom in pomirjevali (benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbitalom, sedativnimi antihistaminiki), priporočamo previdnost.
Duloxetine is a moderate inhibitor of CYP2D6.
5 Zdravila, ki jih presnavlja CYP2D6: duloksetin je zmeren zaviralec CYP2D6.
The co-administration of duloxetine (40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71%, but does not 5 affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended.
Sočasno dajanje duloksetina (40 mg dvakrat dnevno) poveča AUC tolterodina (2 mg dvakrat dnevno) v stanju dinamičnega ravnovesja za 71%, ne vpliva pa na farmakokinetiko njegovega aktivnega 5- hidroksi presnovka, zato ne priporočamo prilagajanja odmerjanja.